Global Therapeutic Plasma Exchange Market Size By Disease Indications (Neurological Disorders, Renal Disorders), By End User (Hospitals, Specialty Clinics), By Geographic Scope And Forecast

Therapeutic Plasma Exchange Market Size And Forecast

Therapeutic Plasma Exchange Market size was valued at USD 1.15 Billion in 2024 and is projected to reach USD 2.19 Billion by 2031, growing at a CAGR of 7.5% from 2024 to 2031.

The expansion of the Therapeutic Plasma Exchange Market can be attributed to advances in therapeutic plasma exchange research and development, an increase in the prevalence of neurological, renal, and hematological disorders, and an expanding variety of therapeutic plasma exchange applications. The rise in R&D activities around the world is helping to propel the Global Therapeutic Plasma Exchange Market forward. The market’s vast range of medical applications is another development driver. In some cases of potentially lethal intoxication, therapeutic plasma exchange is thought to be a promising treatment option.

Global Therapeutic Plasma Exchange Market Definition

Therapeutic Plasma Exchange (TPE) is a technique that involves using an apheresis machine to filter and discard the filtered plasma acquired after passing a patient’s blood through it. The blood is subsequently reinfused with red blood cells as well as any necessary replacement fluids, such as plasma or albumin. TPE, also known as Plasmapheresis, is used to treat a variety of autoimmune illnesses in which the body sees a part of itself as foreign and produces proteins called autoantibodies. TPE can be used to remove significant numbers of disease-causing substances from the body, such as these antibodies, generating symptoms Plasma transfer and plasma perfusion are the two types of plasmaphereses.

A considerable part of plasma containing toxins and other aberrant matter is removed from the other components of blood during plasma exchange and refilled using fluid, usually fresh frozen plasma (FFP) or albumin. For the elimination of aberrant elements in plasma perfusion, the separate plasma is processed with secondary membrane separation or an adsorptive filter. The patient is subsequently given treated plasma, which removes the need for replacement fluids. TPE will eliminate 65 to 70% of disease-causing proteins (antibodies) in the plasma after just one operation.

Therapeutic Plasma Exchange can be used to treat several diseases such as Multiple sclerosis, Neuromyelitis Optica, Cryoglobulinemia, Hyperviscosity syndrome, Recurrent focal segmental glomerulosclerosis, Chronic inflammatory demyelinating polyradiculoneuropathy, Transplant rejection of solid organs such as the kidney and heart, Acute inflammatory demyelinating polyneuropathy (Guillain-Barré Syndrome), Antibody-mediated rapidly progressive glomerulonephritis, Antibody-mediated rapidly progressive. An allergic response to given plasma is possible, however, numerous drugs can help minimize the chances. These medications may be prescribed by a doctor’s treatment plan. Plasma is checked for pathogens and illness during the donation process.

The chances of contracting an infection from given plasma are extremely slim. For a brief period, plasma transfer can modify the fluid equilibrium in the body. During or after the treatment, a person may feel out of breath or have cold arms and hands. If this occurs, a medical expert may decide to take a break from the procedure to permit healing. Plasma interchange can potentially result in transient hypotension and, in rare situations, shock. Plasmapheresis can lower disease immunity.

Global Therapeutic Plasma Exchange Market Overview

Applications in the treatment of a wide range of neurological illnesses are a major growth driver for the Global Therapeutic Plasma Exchange Market. In the cases of neurological diseases such as acute inflammatory demyelinating polyradiculoneuropathy, chronic inflammatory demyelinating polyradiculoneuropathy, myasthenia gravis (MG), and paraneoplastic encephalopathies, TPE is accepted as first-line therapy, either as a stand-alone therapy or in conjunction with other therapies. TPE is also used as second-line therapy for a variety of other neurological diseases, such as acute disseminated encephalomyelitis, chronic focal encephalitis, Lambert-Eaton myasthenic syndrome, Sydenham’s chorea, natalizumab-associated progressive multifocal leukoencephalopathy, multiple sclerosis, and neuromyelitis Optica (NMO, or Devic’s disease), usually in combination with other treatments.

Myasthenia gravis is estimated to impact more than 700,000 people globally, including 36,000 to 60,000 cases in the United States. The market is expected to develop as the prevalence of such neurological illnesses rises. The rise in R&D activities around the world is helping to propel the Global Therapeutic Plasma Exchange Market forward. The market’s vast range of medical applications is another development driver. In some cases of potentially lethal intoxication, therapeutic plasma exchange is thought to be a promising treatment option. Plasma exchange was shown to be as beneficial as hemoperfusion in reducing mortality from 30 to 50 percent with standard therapy to less than 20 percent in phylloid mushroom poisoning.

Plasma exchange has shown to be highly successful in the treatment of potentially lethal antidepressant intoxications caused by 4- and tricyclic antidepressants. It can also assist remove medicines from the bloodstream such as L-thyroxine, diltiazem, verapamil, and carbamazepine. Plasma exchange can also be used to remove protein-bound heavy metals in the blood and phosphor organic intoxications. The price of the apheresis apparatus is a crucial issue in determining whether or not medical professionals and, ultimately, patients would use plasma exchange. Blood banks employ apheresis systems to harvest blood components, while hospitals utilize them in therapeutic plasma exchange operations.

The rising price of apheresis equipment and disposables adds to the overall expense of apheresis. The expanding use of therapeutic plasma transfer for the treatment of a wide range of disorders is likely to provide market participants with potential growth prospects in the future years. Therapeutic plasma exchange (TPE) is used to treat neurological, hematological, renal, and autoimmune conditions that have an immunological etiology that is known or suspected. In pediatric patients, therapeutic plasma exchange procedures are infrequently employed. Furthermore, the increasing number of clinical trials being conducted around the world is likely to give possibilities for the market to expand further.

Global Therapeutic Plasma Exchange Market Segmentation Analysis

The Global Therapeutic Plasma Exchange Market is segmented on the basis of Disease Indications, End User, And Geography.

Therapeutic Plasma Exchange Market, By Disease Indications

• Neurological Disorders
• Renal Disorders
• Hematology Disorders
• Metabolic Disorders
• Others

Based on Disease Indications, The Global Therapeutic Plasma Exchange is divided into Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders, and Others. The market for neurological disorders is likely to take up the majority of the available area. The reason for this is that the majority of the indications in the ASFA recommendations are for neurological illnesses in categories I and II. Plasma exchange treatment has been useful in controlling multiple sclerosis attacks that are abrupt and intense. Furthermore, the rising prevalence of chronic diseases has prompted researchers to seek novel and alternative treatments. Patients with Guillain-Barre syndrome (GBS) who have been treated with plasma interchange exhibited a significant improvement when compared to those who were only given supportive treatment. The segment is expected to be driven by evidence-based plasmapheresis use in neurology and an expansion in industry verticals.

Therapeutic Plasma Exchange Market, By End User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers

Based on End User, The Global Therapeutic Plasma Exchange is divided into Hospitals, Specialty Clinics, and Ambulatory Surgical Centers. Due to the presence of well-developed healthcare infrastructure around the world that can accommodate a patient’s stay for several days, hospitals are projected to have a significant market presence in this segment. The hospital segment’s dominance can be ascribed to a spike in the volume of patients with symptomatic disorders, as well as a growth in the rate of patients who come in through reimbursement schemes like Medicare. The hospital category is also boosted by an increase in healthcare facility consolidation and a growing number of doctors moving from private practices to large-scale hospitals.

Therapeutic Plasma Exchange Market, By Geography

• North America
• Europe
• Asia Pacific
• Middle East & Africa
• Latin America

Based on Geography, The Therapeutic Plasma Exchange Market is classified into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. Due to the presence of well-established hospital infrastructure and globally leading players, Europe is predicted to be the area with the highest business throughout the forecast period. North America and Europe, for example, accounted for the largest portion of the global market.

The presence of a large number of biotech businesses as well as academic and research organizations in these areas have contributed to their dominance. Furthermore, throughout, demand for therapeutic plasma exchange procedures is expected to rise due to the rapid increase and growth in the number of research and academic institutions in these areas. Due to rapidly developing medical centers in countries such As India, China, South Korea, and Malaysia, the Asia-Pacific market is expected to rise at an exponential rate. In the Asia Pacific, China leads the therapeutic plasma marketplace, while India’s market is expected to rise significantly.

Key Players

The “Global Therapeutic Plasma Exchange Market” study report will provide valuable insight with an emphasis on the global market including some of the major players such as Asahi Kasei Corporation, Baxter International, Inc., Terumo Corporation, B. Braun Melsungen AG, Fresenius Kabi AG, Kawasumi Laboratories, Inc., Haemonetics Corporation, Cerus Corporation, Hemacare Corporation, Medica S.p.A., and others.

The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• Terumo BCT and Marker Therapeutics received the first device FDA emergency use authorization (EUA) to treat COVID-19 patients with acute respiratory failure in April 2020.
• Cerus Corporation acquired FDA regulatory permission in May 2020 to manufacture INTERCEPT plasma using a novel, plastic disposable kit.
• Haemonetics Corporation launched its new corporate headquarters in Downtown Boston in December 2019.
• Fresenius joined up with DaVita and other dialysis companies in April 2020 to support a bigger kidney care community in the United States.

Report Scope

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis